Company Overview of AnaptysBio, Inc.
AnaptysBio, Inc., an antibody development company, engages in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology in the Unites states. It is developing ANB020, a pro-inflammatory cytokine antibody that inhibits the activity of interleukin-33; and ANB019, an antibody that inhibits the function of the interleukin-36-receptor. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is based in San Diego, California.
10421 Pacific Center Court
San Diego, CA 92121
Founded in 2005
Key Executives for AnaptysBio, Inc.
Chief Executive Officer, President and Director
Head of Project Management
Chief Development Officer
Compensation as of Fiscal Year 2016.
AnaptysBio, Inc. Key Developments
AnaptysBio Reports ANB020 Top-Line Phase 1 Clinical Trial Results
Oct 3 16
AnaptysBio, Inc. announced top-line results from a single and multiple ascending dose Phase 1 trial of ANB020, a novel anti-interleukin-33 (IL-33) therapeutic antibody. In the double-blind, placebo-controlled Phase 1 trial, 96 healthy volunteer subjects were dosed with either a single subcutaneous or intravenous dose of ANB020 ranging between 10 mg and 750 mg, or four multiple doses of ANB020 ranging between 40 mg and 300 mg over a period of four consecutive weeks. ANB020 was well-tolerated and no dose-limiting toxicities were observed at any dose level. An ex vivo pharmacodynamic assay illustrated that a single dose of ANB020 at certain dose levels was sufficient to suppress IL-33 function for approximately three months post-dosing. AnaptysBio plans to report detailed results from this Phase 1 trial at a future scientific conference. AnaptysBio plans to conduct Phase 2 clinical trials of ANB020 in multiple patient populations, including moderate-to-severe adult atopic dermatitis, severe adult peanut allergy and uncontrolled adult eosinophilic asthma.Â The company recently submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) and a Clinical Trial Application (CTA) to the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) for ANB020 to enable Phase 2 trials.Â The aforementioned Phase 1 trial was conducted in Australia under an approved Clinical Trial Notification (CTN).
AnaptysBio Announces Checkpoint Receptor Agonist Antibody Portfolio
Sep 26 16
AnaptysBio, Inc. announced the development of a portfolio of novel checkpoint receptor agonist antibodies designed for the treatment of human autoimmune diseases. Checkpoint receptors are natural inhibitors of immune cells that function to dampen human inflammatory responses. In oncology, antibodies that block checkpoint receptor function, and thereby upregulate immune cell function, have been approved for the treatment of solid tumors. Human checkpoints comprise a family of receptors that includes CTLA-4, PD-1, LAG-3, BTLA and TIGIT. AnaptysBio believes that immune checkpoint receptors are insufficiently activated in some human inflammatory conditions, and therapeutic modulation with antibodies that augment checkpoint receptor activity has the potential to treat human autoimmune disease. Since checkpoint receptors are expressed by immune cells primarily upon activation, AnaptysBio anticipates that checkpoint receptor agonist antibodies will preferentially suppress disease-causing, auto-reactive immune cells and are therefore less likely to cause broad immunosuppression in patients. Recent studies conducted by AnaptysBio using its therapeutic candidates have demonstrated that checkpoint receptor agonist antibodies are efficacious in a rodent model of graft-versus-host disease. The aforementioned checkpoint receptor agonist antibody portfolio was generated using AnaptysBio's proprietary SHM-XEL antibody discovery platform. AnaptysBio plans to advance the development of checkpoint receptor agonist antibodies as novel therapeutic options for patients suffering from autoimmune diseases.
AnaptysBio, Inc. Presents at 2016 Credit Suisse Antibody Day, Sep-07-2016
Aug 10 16
AnaptysBio, Inc. Presents at 2016 Credit Suisse Antibody Day, Sep-07-2016. Venue: Credit Suisse Offices, One Madison Avenue at 24th Street, 12th Floor, New York, New York, United States. Presentation Date & Speakers: Sep-07-2016, Hamza Suria, Chief Executive Officer, President and Director, Marco Londei, Chief Development Officer.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|